• Four members of Congress disclosed buying ACN in the past 90 days 🦍⚡
• BMO raised its target to $200

Why now

Accenture is a major federal contractor, and four different members of Congress have disclosed buying the stock in the last 90 days -- unusual concentration for one name. Separately, the company announced a strategy partnership with Anthropic on 9/21, and BMO Capital raised its price target to $200 on 9/23, even while keeping a cautious Market Perform rating.

The case

Wall Street agrees too: BMO's $200 target and the new Anthropic AI-strategy tie-up are two separate, more recent reasons to like this on top of the congressional buying above.

🚨 Risk: two firms downgraded ACN in the last two weeks -- Guggenheim to Neutral (9/18) and Wells Fargo to Equal-Weight (9/14) -- both citing slowing growth. Earnings land in early October, before this trade has much room to prove itself, and a soft print would hit the stock before any of the above matters.